Regulation of Akt(ser473) phosphorylation by Choline kinase in breast carcinoma cells
- Boon Tin Chua†1Email author,
- David Gallego-Ortega†2,
- Ana Ramirez de Molina2, 3,
- Axel Ullrich1, 4,
- Juan Carlos Lacal2, 3 and
- Julian Downward5
© Chua et al; licensee BioMed Central Ltd. 2009
Received: 14 July 2009
Accepted: 31 December 2009
Published: 31 December 2009
The serine/threonine kinase PKB/Akt plays essential role in various cellular processes including cell growth and proliferation, metabolism and cell survival. The importance of the Akt pathway is highlighted by the mutation of various components of the pathway such as the PTEN and PI3-kinase (P110α) in human cancers. In this paper, we employed an RNA interference library targeting all human kinases to screen for kinases involved in the regulation of Akt activation, in particular serine 473 phosphorylation. Here, we transfected the MDA-MB 468 breast cell line with the human kinome siRNA library and measured Akt activation using an antibody specific for phosphoserine 473 of Akt.
The screen revealed that phosphorylation of Akt(ser473) can be regulated by more than 90 kinases. Interestingly, phosphorylation of Akt(ser473), but not thr308, can be severely reduced by inhibition of Choline kinase activity via siRNA or small molecule inhibitors. We show here that the regulation of Akt phosphorylation by Choline kinase is PI3K-independent. In addition, xenograft tumors treated with Choline kinase inhibitors demonstrated a statistically significant decrease in Akt(ser473) phosphorylation. Importantly, the reduction in phosphorylation correlates with regression of these xenograft tumors in the mouse model.
High Choline kinase expression and activity has previously been implicated in tumor development and metastasis. The mechanism by which Choline kinase is involved in tumor formation is still not fully resolved. From our data, we proposed that Choline kinase plays a key role in regulating Akt(ser473) phosphorylation, thereby promoting cell survival and proliferation.
Akt or Protein kinase B, is a serine/threonine kinase that plays an important role in regulating a number of cellular processes such as growth, metabolism and survival (reviewed in ). The importance of the Akt pathway is highlighted by the mutation of various components of the pathway in human cancers such as the PTEN and PI3-kinase (P110α), which occur in more than 30% of human tumors (reviewed in ). In recent years, much has been invested in the search for other Akt substrates in the hope of understanding the different cellular processes controlled by Akt. Currently over fifty Akt substrates have been identified.
For Akt to achieve full activation, phosphorylation is needed at both serine 473 (ser473) of the hydrophobic tail and threonine 308 (thr308) of the activation motif, upon growth factor ligation to the receptor tyrosine kinases . The extra-cellular growth signal is transduced via the Ras protein resulting in the activation of PI3K. The lipid kinase phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) which acts as a secondary messenger to recruit Akt via its PH domain to the peripheral membrane. Similarly, PDK1 is also recruited via its PH domain to phosphorylate thr308 of Akt. To date, there are several candidate kinases fulfilling the role of PDK2, for the ser473 residue, the most likely candidate being the mTORC2 . Others include DNA-PK, ILK and some PKCs [5–9].
Choline kinase (ChoK), is a lipid kinase that phosphorylates choline to generate phosphoryl choline (PCho). PCho serves as the first step in the Kennedy pathway for the generation of phosphatidylcholine , a major lipid component of the cellular membrane. In the last few years, high PCho and ChoK activity has been found in several human tumor types including breast, lung, colon and prostate [11, 12]. There is a strong clinical correlation between ChoK expression level and tumor malignancy in breast, lung and bladder cancer [13, 14]. Several reports have also demonstrated that with the inhibition of ChoK either by siRNA or small molecule inhibitors, there is a marked reduction in proliferation and mitogenic properties and a decrease in breast cancer cell viability has being reported in combination with 5-fluorouracil [15, 16]. A full understanding of how this lipid kinase and its downstream substrates contribute to tumorigensis has yet to be disclosed, although some previous studies clearly correlate ChoK regulation with Rho A signaling, and transcriptome analysis of ChoK overexpression demonstrates its effects on cell cycle regulation and apoptosis impairment [17–19]. Previously, it has been shown that PCho confers mitogenic properties to mouse fibroblasts upon stimulation by PDGF or FGF [20, 21].
In this work, we searched for kinases that could regulate Akt activity specifically at ser473. Using a human kinome siRNA library, we silenced individual kinases systematically in MDA-MB 468 cells to screen for candidate kinases that regulate Akt phosphorylation at this site using an indirect immunofluorescent method. In our system, MDA-MB 468 breast carcinoma cells were used for its high endogenous Akt phosphorylation in the absence of growth factors due to PTEN mutation. With the high content imaging system, we found that ~12% of the human kinome could directly or indirectly regulate Akt(ser473) phosphorylation. Of which, silencing of the ChoK, reduces Akt(ser473) phosphorylation significantly, suggesting its potential role as a regulator of PDK2.
Silencing of Choline kinase A or B reduces Akt serine473 phosphorylation in MDA-MB 468 cells
The effects of ChoK A or B on Akt phosphorylation were validated using deconvoluted siRNAs as well as the more specific On-Target plus siRNA. As shown in fig 1B, silencing of both ChoK A and B resulted in strong reduction on pAkt(ser473) by the western blot analysis. Using real time PCR, successful knock down of ChoK A and B were confirmed (fig 1C).
ChoK regulates Akt activity
It has previously been demonstrated that the mTor complex 2 (mTORC2), of which Rictor is a component, is responsible for Akt(ser473) phosphorylation in a number of different cell systems . To assess the contribution of the mTORC2 pathway in our system, mTor or Rictor were silenced (fig 2B). Immunoblotting with the pAkt(ser473) antibody demonstrated that ChoK A's effect on Akt(ser473) phosphorylation is equivalent to Rictor's, with more than 70% reduction following silencing of ChoK A or Rictor.
To demonstrate that the role of ChoK in Akt activation was not cell type specific, we performed the same silencing experiments on MDA-MB 231 cells. Two days after the siRNA transfection, the cells were serum-starved overnight and Akt activity was induced with the addition of Insulin-like Growth Factor (IGF) for 15 minutes. Here, in the cells with ChoK A or B or both silenced, stimulation with growth factor resulted in approximately 50% less Akt(ser473) phosphorylation compared to control cells (fig 2C).
To further demonstrate the regulation of Akt by ChoK, we overexpressed, either vector, ChoK A or B plasmids, in MCF7 cells. The overexpressed lipid kinases are active as shown in fig 2D. 24 hours posttransfection an increase in Akt(ser473) phosphorylation was observed (fig 2E).
ChoK inhibitors inhibit ChoK activity and Akt phosphorylation
ChoKα regulates Akt phosphorylation down stream of PI3K
Mn58b treatment slowed tumor growth through the inhibition of Akt phosphorylation
In this work, we used human kinome siRNA library to screen for kinases that positively regulate Akt phosphorylation at the ser473 residue in the breast cancer cell line, MDA-MB 468. MDA-MB 468 cells have an intrinsic PTEN mutation resulting in high endogenous Akt activity in the absence of growth factors. The systematic silencing of individual kinases in these cells with the RNA interference library allows us to identify kinases that alter Akt(ser473) phosphorylation. In combination with the high content screening microscope, we found a total of 92 kinases that upon knock down, resulted in 20 to 60% decrease in Akt(ser473) phosphorylation. In the screen setup, due to the "edge" effect of the 96 well plates, we noted that the standard deviation of these wells were high. Hence, these samples were not considered further. Regardless, the screen enables us look at 500 kinases and their effect on Akt phosphorylation.
Further validation had shown that ChoKα, plays an important role in regulating Akt(ser473) phosphorylation. Our data showed that ChoK is unlikely to act on the components upstream of Akt such as the PI3K signaling axis. This is showed by the ability of PH-GFP fusion protein to be recruited to the peripheral membrane in the presence of IGF stimulation in ChoK-silenced cells. These results demonstrated that PI3K is functional and able to generate PIP3 for the recruitment of both Akt and PDK1 as shown with the intact Akt(thr308) phosphorylation in these cells. Interestingly, other than the reported effects on Akt(ser473) phosphorylation, we also observed a decrease in Erk phosphorylation in ChoK-silenced cells. Since silencing of ChoK does not affect PI3K activity, it is unlikely that the reduced Erk phosphorylation is due to an inactivation of the upstream Ras. It is however possible that the reduction of Erk phosphorylation is due to yet unknown effects of this lipid kinase upon the Raf/MEK pathway, which will requires further investigation. Alternatively, the downstream effect on Erk signaling could arise from the cross talk between PI3K/Akt pathway and the Raf/MEK pathway, as shown with PI3K inhibitor, LY294002 treatment.
Although our data from both the RNAi silencing and small molecule inhibitor studies clearly demonstrate an interesting role of ChoK on Akt(ser473) phosphorylation, it is unlikely that the lipid kinase phosphorylate Akt(ser473) directly since our data with the ChoK inhibitors demonstrated a distinct lag time between ChoK activity inhibition and Akt phosphorylation. Only ~50% reduction in Akt(ser473) phosphorylation was observed when 70% of ChoKα activity was inhibited after 2 h of Mn58b treatment. A similar observation was made for TCD828 treated cells with a 56% reduction in Akt(ser473) phosphorylation after 0.5 h incubation with TCD828 which inhibited ~85% of ChoKα activity. In addition, we did not observe a physical interaction between Akt and ChoKα via co-immunoprecipitation (data not shown). Nonetheless, the evidence presented by xenograft regression with reduced Akt(ser473) phosphorylation and strong inhibition in Akt(ser473) phosphorylation after prolong treatment with ChoK inhibitors strongly support our data, suggesting a probable role of ChoKα as a regulator of PDK2, controlling the phosphorylation of Akt at ser473. Alternatively, the effect of ChoKα on Akt(ser473) phosphorylation could also arise through the inactivation of the Akt phosphatase. Previously, PH domain leucine-rich repeat protein phosphatase, PHLPP was identified by Gao et al as the phosphatase that dephosphorylate Akt1(ser 473) . Further experiments will be required to definitively demonstrate these unexpected properties of ChoKα.
These findings are particularly exciting for two reasons. Firstly, there are several potential kinases that phosphorylate Akt(ser473). Of which, mTORC2 effect on Akt is significantly reproducible in many different cell types. In our work, we had shown that silencing of the lipid kinase, ChoK, resulted in reduced Akt(ser473) phosphorylation to a similar degree as observed following the silencing of Rictor, a member of the mTORC2 complex. Secondly, reminiscent of the regulators of the Akt pathway, there is evidence that ChoK can serve as marker for tumor progression. It has been shown that ChoK activity and its product, PCho, are increased in tumor cells relative to the normal cells [12, 23–27]. This has been established in tumors of different tissue origins and in particular those derived from the breast [28, 29]. It has also been demonstrated in vivo by NMR, where increase levels of PCho are frequently associated with cell malignancy [30–32]. All these results have established PCho as a malignancy marker with potential use in cancer diagnosis [28, 33]. Our data demonstrate the presence of a novel cross talk between the lipid kinase and Akt pathway
Although the precise role of ChoK in these cancer cells is still not fully understood, it has been postulated that this lipid kinase is likely to be upregulated in order to provide lipid components for the actively dividing cancer cells. In addition, the PCho appears to induce mitogenic signaling, promoting cellular proliferation. Currently, there is an active effort in the development of ChoK inhibitors. Results from Mn58b, a well characterized ChoK inhibitor with in vitro and in vivo antiproliferative and antitumoral effect in mice xenografts provides strong support to this concept.
Based on the information provided here and previous publications, we propose that ChoK displays oncogenic activity through activation of specific signaling pathways that impinge on cell proliferation and survival. One important signaling pathway affected is its interaction with Akt in cancer cells. However, we are uncertain of how this interaction regulates Akt other than it is required for ser473 phosphorylation. One probable hypothesis is that ChoK acts as an adaptor for a yet unidentified Akt(ser473) kinase. Alternatively, it would be interesting to determine if there is presence of any relationship between ChoK and mTORC2 activity.
Cell line and reagents
All cell lines were purchased originally from ATCC. MDA-MB 468, MDA-MB 231 and MCF7 were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum. Cells were incubated in 37°C incubator with 10% carbon dioxide. ChoK A and B plasmids, monoclonal anti-ChoKα, Mn58b and TCD828 are kind gifts from Prof Lacal. All reagents unless specified are from Sigma-Aldrich (Saint Louis, MO).
Human kinome siRNA screen setup
The 779 human kinase siRNA kinome library was supplied by Dharmacon as SMARTpool on 10 × 96 well plates. Non-Targeting siRNA or scrambled siRNA (scr) is used as negative control. 7500 MDA-MB-468 cells were seeded in 96 well plates the day before transfection. 70 nM siRNA were transfected using Oligofactamine according to manufracturer's instruction in triplicates. 72 hours post transfection, cells were fixed and proceeded to indirect immunofluorescent staining.
Indirect Immunofluorescent labeling
After desired period of treatment, cells were washed once in PBS and fixed in 4% paraformaldehyde. Cells were permeabilised with 0.1% Triton X-100 followed by blocking with 3% BSA/PBS for 1 h and incubation with 1:250 anti-phospho-Akt(ser473) in 0.1% BSA/PBS overnight at 4°C. Subsequently, cells were washed followed by the addition of anti-rabbit secondary antibodies conjugated with Alexa Fluor 488 for 1 h. Nuclei were counterstained with 250 ng/ml H-33342 (Molecular Probes). Fluorescent images were collected and analysed using either Discovery-1 (Molecular Devices) or confocal microscope.
Phospho-Akt(ser473) signal quantitation
Images of siRNA transfected cells after immunostaining with anti-phospho-Akt(ser473) were acquired using Discovery-1, high content screening fluorescent microscope, with 10× objectives. Three fields were imaged per well and total of 9 images were captured per kinase knock down. Images were analysed by MetaMorph. The phospho-Akt signal per cell per kinase knock down was calculated by obtaining total intensity (from the Fluorohore) of the signal divided by total number of cells imaged. This reading was compared to the non-targeting siRNA transfected cells (scr, set to be 100%) and background fluorescence reading (set to be 0%). Standard deviation was obtained from triplicate experiments.
siRNA targeting ChoKA, ChoKB, Akt1/2 and non-targeting control (scr) were purchased from Dharmacon (Dharmacon RNAi Technologies, Lafayette, CO) as SMARTpool or deconvoluted set of 4. Transfections using Oligofectamine (Invitrogen, San Diego, CA) were performed following the manufacturer's instructions.
RNA were isolated from cells using RNeasy kit from Qiagen. 500 ng total RNA was used to synthese complementary DNA using Superscript III first strand synthesis for RT-PCR (Invitrogen). 2 μl of the cDNA were loaded for Real time PCR using ABI 7500 with SYBR green mix (Applied Biosystems) and respective primer sets. ChoKA Forward: TAGGTTTGCCCTTGCATCTCA reverse: TCACACCCCAAGCTTCCTCTT ChoKB Forward: GTACATCCCAAGTCGGCCATT reverse: GCTCCTTGGTGAAAGGCATCT GAPDH Forward: CCCTTCATTGACCTCAACTACAT reverse: TCCTGGAAGATGGTGATGG
Transient transfections using Lipofectamine™ 2000 (Invitrogen) were performed following the manufacturer's instructions.
Cells were seeded the day before on 6 well dish. Mn58b or TCD828 were added to the medium for indicated time and concentration. For MDA-MB 231, after incubation with inhibitors, 50 ng/ml of IGF was added for 15 mins before whole cell lysate were harvested for western blot.
Cells were lysed in 1% triton lysis buffer. Protein concentration was determined using BCA assay (Thermo scientific). 30 μg of protein lysate were separated on 4-12% Tri-glycine gel (Invitrogen). Protein were transferred to PVDF membrane and immunoblotted with anti-phospho-Akt(ser473), antiphospho-Akt(thr308), anti-phospho-Erk1/2, anti-phospho-GSK3β (Cell Signaling Technology, Beverly, MA), anti-ChoKα, anti-HSP60, anti-tubulin, anti-GAPDH. Image J program was used to quantified the western blot signal. Phospho-Akt(ser473) signal were normalized to the respective total Akt. Difference in phosphorylation was obtained by comparing to scr control or untreated cells (set as 1).
Choline kinase activity assay
ChoK activity were assayed as described in .
In vivo Anti-tumor Assays
Human breast tumor xenografts were established by subcutaneous injection of tumor cells in each flank of nu/nu immunosuppressed mice. Mice were kept under standard laboratory conditions according to the guidelines of the Spanish government. Cells were resuspended in Dulbecco's modified Eagle's medium just before inoculation (2 × 106 cells/0.1 ml). When tumors reached a mean volume of 0.1 cm3, mice were randomized to control and treatment groups (6 mice per group). Treatments with Mn58b (and vehicle for control mice) were performed intraperitoneally for two week of treatmentseparated by 9 days. In the treatment weeks, the schedule was three doses of 2 mg/kg each, three times in the week. Tumors were monitored at least twice a week by measuring the major (D) and minor (d) diameters, and tumor volume was calculated as V = (D × d2)/2. The drug was well tolerated by the mice, with no significant effects on general appearance or behavior. Toxicity effects were confirmed by using hairy mice, treated under similar conditions of dose and schedule. No effects on fur, general appearance, or behavior were observed. No reduction in body weight was observed
Tumors removed from mice were fixed and IHC performed according to .
Choline kinase A gene
Choline kinase A protein
phosphoinositide dependent protein kinase 1
nuclear magnetic resonance.
We are grateful to Daniel Zicha and his lab for their assistance with the microscopy work. David Gallego-Ortega was a fellow from Comunidad de Madrid/FPI 2004. This work was funded by Cancer Research UK and following grants to Juan Carlos Lacal: Ministerio de Ciencia e Innovación (SAF2008-03750), Comunidad de Madrid (S-BIO/0280/2006), Ministerio de Sanidad (RETICC RD06/0020/0016, and Acción Transversal del Cáncer, FIS, Instituto de Salud Carlos III) and Agency for Science, Technology and Research, Singapore
- Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV: The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene. 2005, 24 (50): 7482-7492. 10.1038/sj.onc.1209088View ArticlePubMed
- Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004, 30 (2): 193-204. 10.1016/j.ctrv.2003.07.007View ArticlePubMed
- Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, Gaffney P, Reese CB, MacDougall CN, Harbison D, Ashworth A, Bownes M: 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol. 1997, 7 (10): 776-789. 10.1016/S0960-9822(06)00336-8View ArticlePubMed
- Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005, 307 (5712): 1098-1101. 10.1126/science.1106148View ArticlePubMed
- Partovian C Simons M: Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. Cell Signal. 2004, 16 (8): 951-957. 10.1016/j.cellsig.2004.01.008View ArticlePubMed
- Lu D, Huang J, Basu A: Protein kinase Cepsilon activates protein kinase B/Akt via DNA-PK to protect against tumor necrosis factor-alpha-induced cell death. J Biol Chem. 2006, 281 (32): 22799-22807. 10.1074/jbc.M603390200View ArticlePubMed
- Kawakami Y, Nishimoto H, Kitaura J, Maeda-Yamamoto M, Kato RM, Littman DR, Leitges M, Rawlings DJ, Kawakami T: Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J Biol Chem. 2004, 279 (46): 47720-47725. 10.1074/jbc.M408797200View ArticlePubMed
- Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S: Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA. 1998, 95 (19): 11211-11216. 10.1073/pnas.95.19.11211PubMed CentralView ArticlePubMed
- Hill MM, Feng J, Hemmings BA: Identification of a plasma membrane Raft-associated PKB Ser473 kinase activity that is distinct from ILK and PDK1. Curr Biol. 2002, 12 (14): 1251-1255. 10.1016/S0960-9822(02)00973-9View ArticlePubMed
- Wong JT, Chan M, Lee D, Jiang JY, Skrzypczak M, Choy PC: Phosphatidylcholine metabolism in human endothelial cells: modulation by phosphocholine. Mol Cell Biochem. 2000, 207 (1-2): 95-100. 10.1023/A:1007054601256View ArticlePubMed
- Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F, Rosell R, Lacal J: Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun. 2002, 296 (3): 580-583. 10.1016/S0006-291X(02)00920-8View ArticlePubMed
- Bhakoo KK, Williams SR, Florian CL, Land H, Noble MD: Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res. 1996, 56 (20): 4630-4635.PubMed
- Ramirez de Molina A, Gutierrez R, Ramos MA, Silva JM, Silva J, Bonilla F, Sanchez JJ, Lacal JC: Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene. 2002, 21 (27): 4317-4322. 10.1038/sj.onc.1205556View ArticlePubMed
- Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez de Molina V, Cejas P, Skrzypski M, Gallego-Ortega D, de Castro J, Casado E, Garcia-Cabezas MA, Sanchez JJ, Nistal M, Rosell R, Gonzalez-Baron M, Lacal JC: Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol. 2007, 8 (10): 889-897. 10.1016/S1470-2045(07)70279-6View ArticlePubMed
- Glunde K, Raman V, Mori N, Bhujwalla ZM: RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res. 2005, 65 (23): 11034-11043. 10.1158/0008-5472.CAN-05-1807View ArticlePubMed
- Mori N, Glunde K, Takagi T, Raman V, Bhujwalla ZM: Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res. 2007, 67 (23): 11284-11290. 10.1158/0008-5472.CAN-07-2728View ArticlePubMed
- Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Lacal JC: Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene. 2004, 23 (50): 8247-8259. 10.1038/sj.onc.1208045View ArticlePubMed
- Ramirez de Molina A, Gallego-Ortega D, Sarmentero-Estrada J, Lagares D, Gomez Del Pulgar T, Bandres E, Garcia-Foncillas J, Lacal JC: Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. Int J Biochem Cell Biol. 2008, 40 (9): 1753-1763. 10.1016/j.biocel.2008.01.013View ArticlePubMed
- Ramirez de Molina A, Gallego-Ortega D, Sarmentero J, Banez-Coronel M, Martin-Cantalejo Y, Lacal JC: Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res. 2005, 65 (13): 5647-5653. 10.1158/0008-5472.CAN-04-4416View ArticlePubMed
- Cuadrado A, Carnero A, Dolfi F, Jimenez B, Lacal JC: Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene. 1993, 8 (11): 2959-2968.PubMed
- Jimenez B, del Peso L, Montaner S, Esteve P, Lacal JC: Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation. J Cell Biochem. 1995, 57 (1): 141-149. 10.1002/jcb.240570114View ArticlePubMed
- Gao T, Furnari F, Newton AC: PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 2005, 18 (1): 13-24. 10.1016/j.molcel.2005.03.008View ArticlePubMed
- Lacal JC, Moscat J, Aaronson SA: Novel source of 1, 2-diacylglycerol elevated in cells transformed by Ha-ras oncogene. Nature. 1987, 330 (6145): 269-272. 10.1038/330269a0View ArticlePubMed
- Lacal JC: Diacylglycerol production in Xenopus laevis oocytes after microinjection of p21ras proteins is a consequence of activation of phosphatidylcholine metabolism. Mol Cell Biol. 1990, 10 (1): 333-340.PubMed CentralView ArticlePubMed
- Macara IG: Elevated phosphocholine concentration in ras-transformed NIH 3T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown. Mol Cell Biol. 1989, 9 (1): 325-328.PubMed CentralView ArticlePubMed
- Ratnam S, Kent C: Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. Arch Biochem Biophys. 1995, 323 (2): 313-322. 10.1006/abbi.1995.9959View ArticlePubMed
- Ramirez de Molina A, Rodriguez-Gonzalez A, Penalva V, Lucas L, Lacal JC: Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells. Biochem Biophys Res Commun. 2001, 285 (4): 873-879. 10.1006/bbrc.2001.5250View ArticlePubMed
- Eliyahu G, Kreizman T, Degani H: Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer. 2007, 120 (8): 1721-1730. 10.1002/ijc.22293View ArticlePubMed
- Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F: Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005, 65 (20): 9369-9376. 10.1158/0008-5472.CAN-05-1146View ArticlePubMed
- Negendank W: Studies of human tumors by MRS: a review. NMR Biomed. 1992, 5 (5): 303-324.View ArticlePubMed
- Al-Saffar NM, Troy H, Ramirez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL: Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res. 2006, 66 (1): 427-434. 10.1158/0008-5472.CAN-05-1338View ArticlePubMed
- Glunde K Serkova NJ: Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics. 2006, 7 (7): 1109-1123. 10.2217/14622422.214.171.1249View ArticlePubMed
- Katz-Brull R, Lavin PT, Lenkinski RE: Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst. 2002, 94 (16): 1197-1203.View ArticlePubMed
- Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Ramos MA, del Carmen Nunez M, Campos J, Lacal JC: Inhibition of choline kinase as a specific cytotoxic strategy in oncogenetransformed cells. Oncogene. 2003, 22 (55): 8803-8812. 10.1038/sj.onc.1207062View ArticlePubMed
- Guo K, Li J, Wang H, Osato M, Tang JP, Quah SY, Gan BQ, Zeng Q: PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo. Cancer Res. 2006, 66 (19): 9625-9635. 10.1158/0008-5472.CAN-06-0726View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.